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Abstract
Background: Our previous double-blinded, placebo-con-
trolled cross-over study indicated that a nutritional supple-
ment named lycopene-rich tomato nutrient complex (TNC) 
can protect from UVA1-induced (340–400 nm) and UVA- 
(320–400 nm)/UVB-induced (280–320 nm) upregulation of 
molecular markers associated with oxidative stress, inflam-
mation, and ageing. Objectives: in the current double-blind, 
randomized, placebo-controlled multicenter study, we ana-
lyze whether a similar, synergistic carotenoid-rich TNC can 
protect from broadband UVB-induced threshold erythema 
formation assessed as increase in minimal erythemal dose 
(MED) reading, the intensity of erythema formation, and the 
upregulation of molecular markers associated with inflam-
mation and immunosuppression, and whether this corre-
lates with carotenoid blood levels. Methods: One hundred 
and forty-nine healthy volunteers were randomized to two 
groups and subjected to a 5-week washout phase, followed 
by a 12-week treatment phase receiving either 15 mg lyco-
pene, 5.8 mg phytoene and phytofluene, 0.8 mg β-carotene, 
5.6 mg tocopherols from tomato extract, and 4 mg carnosic 
acid from rosemary extract per day or placebo made from 
medium-chain triglycerides. At the end of each phase, MED 
determination, UVB irradiation, chromametry, biopsies, and 
blood samples were undertaken. Results: The active supple-
ment was well tolerated. Interestingly, no significant differ-
ence was seen in the MED between the active-supplement 
and placebo groups, as determined by visual grading by ex-
pert assessors. Of note, the carotenoid-containing supple-
ment significantly protected against UVB-induced erythema 
formation measured as Δa* after the intervention minus Δa* 
after the washout phase as compared to the placebo. More-
over, intake of the active supplement significantly protected 
against UVB-induced upregulation of IL6 and TNFα as com-
pared with the intake of placebo. Lastly, carotenoid plasma 
levels were significantly increased. Conclusion: This well-tol-
erated carotenoid-containing supplement significantly pro-
tected against UVB-induced erythema formation and upreg-
ulation of proinflammatory cytokines in healthy volunteers.
© 2019 The Author(s)
Published by S. Karger AG, Basel
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NonCommercial-NoDerivatives 4.0 International License (CC BY-
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Introduction
The concept of oral photoprotection by antioxidant 
micronutrients gained very popular over the last decades 
[1, 2]. In case of topical sunscreens, the sun protection 
factor is a simple and noninvasive tool to quantify the 
photoprotective activity. The latter is defined as a quo-
tient of the minimal erythemal dose (MED) under treat-
ment divided by the MED without intervention repre-
senting a measure for acute deleterious effects of UV ir-
radiation [3]. An increased MED after intervention with 
a nutritional supplement can also therefore be used as an 
indicator of photoprotection in studies of potential oral- 
ly ingested photoprotectants. A special focus was on 
β-carotene, which had been shown in a meta-analysis to 
provide significant protection against UV-induced ery-
thema if taken at least over a period of 10 weeks [4]. Safe-
ty concerns after long-term intake of β-carotene at non-
physiological levels arose when adverse effects on the in-
cidence of lung cancer in smokers and workers exposed 
to asbestos were found [5]. To circumvent this issue, oth-
er carotenoids such as lycopene or lutein came into focus. 
Recently, a double-blinded, placebo-controlled cross-
over study has shown that both these ingredients provid-
ed significant protection against UVA- or UVA/UVB-in-
duced upregulation of UV-inducible markers such as 
heme oxygenase 1, intercellular adhesion molecule 1, and 
matrix-metalloproteinase 1 [6]. Some limitations of that 
study were (i) the relatively low number of volunteers in-
cluded and (ii) the lack of showing an effect on the phys-
iological erythemal skin response after intervention with 
the active supplement. In order to complement and 
strengthen the results of that study, we therefore per-
formed a double-blind, randomized, placebo-controlled, 
multicenter follow-up study to assess as primary objec-
tive the effect of carotenoid-rich tomato nutrient com-
plex (TNC; containing and rosemary extract) on the acute 
UV radiation-mediated erythemal skin response; i.e., (i) 
MED and (ii) intensity of erythema, compared with the 
placebo cohort following 12 weeks of twice daily oral sup-
plement. As secondary objective, we wanted to evaluate 
the effect of carotenoid-rich TNC compared to that of 
placebo after 12 weeks of b.i.d. (twice a day) supplemen-
tation on skin biopsy biomarkers indicative for immuno-
suppression or inflammation. Analysis of UV-induced 
gene expression was very helpful to address photodamage 
to human skin in vivo in the previous study [6]. With re-
gards to UVB, IL1α was shown to be upregulated in kera-
tinocytes in vitro and in vivo [7, 8]. IL10 was shown to be 
induced in keratinocytes in vitro and in human skin in 
vivo, where it exerts profound immunosuppressive ac-
tivities [9]. Proinflammatory cytokines such as TNFα and 
IL6 are induced upon UVB treatment in keratinocytes 
and in humans on mRNA and protein level [10, 11]. For 
a detailed review on UVB-induced cytokine production 
by keratinocytes or Langerhans cells, see [12].The listed 
proinflammatory cytokines act in a cascade fashion to in-
duce inflammation with initial release by keratinocytes or 
inflammatory cells in the skin and subsequent synergiz-
ing with UV-irradiated keratinocytes to further increase 
their cytokine production finally affecting local and sys-
temic immunosurveillance [12, 13].
Materials and Methods
Materials
Carotenoid-rich TNC soft gel capsules contained 7.5 mg lyco-
pene, 2.9 mg phytoene and phytofluene, 0.4 mg β-carotene, 2.8 mg 
tocopherols from tomato extract, and 2 mg carnosic acid from 
rosemary extract per capsule (2 capsules per daily dose). The pla-
cebo was packaged in an identically looking soft gel capsule and 
consisted of medium-chain triglycerides. Both treatments were 
obtained from Lycored Ltd., Be’er Sheva, Israel.
Study Design
This study was approved by the local Ethics Committees of (i) 
the Heinrich Heine University, Düsseldorf, Germany (reference 
No. 4194), and (ii) the University of Dundee, Scotland, UK (No. 
SC015096). It was conducted at the IUF – Leibniz-Research Insti-
tute for Environmental Medicine, Düsseldorf, Germany, and at the 
Photobiology Unit, Department of Dermatology, Ninewells Hos-
pital and Medical School, Dundee, UK, according to the ethical 
rules stated in the principles of the Declaration of Helsinki and the 
International Council for Harmonisation of Technical Require-
ments for Pharmaceuticals for Human Use. We conducted a ran-
domized, double-blind, placebo-controlled, parallel-group, multi-
center clinical trial in which each subject was randomized to re-
ceive carotenoid-rich TNC or placebo for a period of 12 weeks in 
a parallel-group design. A total of 149 subjects (female or male) 
were enrolled into the study, and 145 subjects completed the trial 
as planned. The treatment groups were stratified based on the age 
category, gender, and smoking to ensure equal distribution of such 
population within the two treatment arms (Table 1). The group 
taking the active supplement included 75 volunteers (56 female, 19 
male), and the group taking placebo consisted of 74 volunteers (59 
female, 15 male). The age distribution did not differ in both arms 
of the study (mean ages were 40.9 and 40.9 years). The age of the 
volunteers ranged from 20 to 50 years. Current smokers were very 
rare; in the carotenoid-rich TNC group, there were 5 smokers 
(7%), and in the placebo group 3 (4%). For ethical reasons, only 
two-thirds of the volunteers were asked for biopsies to be analyzed 
for expression of molecular markers. The subjects enrolled were 
distributed according to an online block randomization service by 
the sponsor; block size was 2, allocation ratio 1: 1. Volunteers and 
investigators were unaware of the treatment.
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All individuals were of good general health with a body mass 
index ≤30. Their Fitzpatrick skin type was type I–II. With regards 
to eating habits, a normal diet and the willingness to follow a lyco-
pene- and antioxidant-restricted diet was requested. Exclusion cri-
teria were sunbed use and pregnancy. The study was conducted 
between January 2014 and September 2016.
Determination
The MED was determined with a dermalight® 80 MED tester 
(Dr. Hönle, Gilching, Germany) in the broadband UVB range on 
visits 2 and 7 on both sides of the buttock by visual grading under-
taken by expert assessors. The dermalight 80 MED tester serves for 
the definition of the MED according to the choice of the light 
source and skin type. The device contains a foil with 10 different 
test fields. The varying dosage in the test fields is caused by varying 
sizes of outlets and therefore varying UV irradiation.
Chromametry
MED was read 24 h after MED testing. Directly after the MED 
reading, a dose of 1.25 MED was applied on an additional field 
(12 × 12 mm) of the buttock for skin color determination by 
chromametry (Chromameter CR400; Konica Minolta Sensing 
Europe B.V., Bremen, Germany) and for taking biopsies with a 
dermalight 80 MED tester (Dr. Hönle). The erythema formation 
was measured as change of skin color a*, which reflects the red-
ness of the skin according to the Commission Internationale de 
l’Eclairage, as evaluated in [14]. We followed the recommended 
guidelines for skin color determination [15]. In this regard, color 
is expressed in a device-independent, three-dimensional color 
space reflected by the variables L*, b*, and a*. The latter a* values 
represent green in the negative direction and red in the positive 
direction. The dose of 1.25 MED was selected according to prior 
experience [16].
Assessment of Blood Samples
Blood samples for carotenoid determination were collected af-
ter a 5-week washout phase, at randomization, after 4 weeks of 
treatment, and at the end of the study in heparinized tubes and 
immediately centrifuged. The plasma was stored at –80  ° C until 
analysis for carotenoids such as lycopene, α-, and β-carotene by 
high-performance liquid chromatography, as previously described 
[6, 17, 18]. In addition, the colorless carotenoids phytofluene and 
phytoene were measured because these precursors of carotenoids 
absorb radiation in the UV range [19, 20].
Assessment of Gene Expression
Biopsies were taken 24 h after chromametry using 1.25 MED at 
visits 4 and 8 (Fig. 1b), snap frozen in liquid nitrogen and stored 
at –80  ° C until further analysis as, previously described [21–23]. 
For the evaluation of UV-induced gene expression, the 2(–ΔΔc(t)) 
method is used [24]. Gene expression is indicated as x-fold induc-
tion versus an unirradiated control. Primer pairs were as follows:
IL1α (forward 5′-TGTATGGACTGCCCAAGATGAA-3′, 
reverse 5′-ACTACCTGTGATGGTTTTGGGTATC-3′, NM_ 
000575.4) [25]; IL6 (forward 5′-CCTCGAGCCCACCGGGAA-
CG-3′, reverse 5′-AA-CTGGACCGAAGGCG-CTTGTG-3′, NM_ 
000600.4) [26]; IL10 (forward 5′-AAGACCCAGACATC-AA-
GGCG-3′, reverse 5′-AATCGATGACAGCGCCGTAG-3′, NM_ 
000572.3) [27]; TNFα (forward 5′-GGAGAAGGGTG-ACC- 
GAC TCA-3′, reverse 5′-TGCCCAGACTCGGCAAAG-3′, NM_ 
000594.3) [28]; and 18S rRNA as housekeeping gene (forward 
5′-GCCGCTAGAGGTGAAATTCTTG-3′, reverse 5′-CATTCTTG- 
GCAAATGCTTTCG-3′, X03205.1) [29].
Sample Size and Statistical Evaluation
Sample size calculation was based on previously conducted 
studies by Lycored employing different carotenoid-rich formula-
tions (Lyc-O-Mato and Lyc-O-Guard drink) for the primary end-
point “protection against ultraviolet (UV) light-induced erythe-
ma,” such as [19, 30, 31]. The sample size corresponds to an effect 
size difference at 12 weeks between the two groups, with a power 
of 80% and a drop-out rate of 10%.
Data management and randomization were done by Medistat 
Ltd. (Tel-Aviv, Israel). Additional studies were performed in-
house with the help of SigmaPlot (version 14.0). Normality of the 
data was tested using the Shapiro-Wilk test. For comparison of 
significant differences, the Kruskal-Wallis one-way ANOVA on 
ranks, t test, or Mann-Whitney rank sum tests were performed.
Results and Discussion
For the active arm of the study, 75 volunteers were re-
cruited, and 71 completed the study. For the placebo arm, 
all 74 recruited volunteers also finished the trial (Fig. 1a).
The treatment was safe and well tolerated, and no seri-
ous adverse events were observed within the two study 
populations. Only one severe adverse event diagnosed as 
pityriasis rosea occurred in the group with carotenoid-
rich TNC intake. In addition, one volunteer in the same 
group discontinued the study due to mild eczema. Com-
pliance was good in both arms, which was reflected by the 
carotenoid levels determined at the end of the 5-week 
washout phase (visit 2), after 4 weeks of intake (visit 5), 
and at the end of the 12 weeks of intake (visit 8) (Fig. 1b, 
2a–c) from blood samples. In detail, after 5 weeks of diet 
Table 1. Baseline demographics and characteristics
Carotenoid-rich 
TNC
Placebo
Participants, n 75 74
Females, n (%) 56 (75) 59 (80)
Males, n (%) 19 (25) 15 (20)
Mean age (SD), years 40.9 (10.3) 40.9 (10.1)
Mean BMI (SD) 25.8 (2.8) 25.3 (3.0)
Mean initial lycopene level, nM 676 710
Median initial lycopene level, nM 646 670
Mean initial phytofluene level , nM 65 80
Median initial phytofluene level, nM 51 55
Mean initial phytoene level, nM 54 46
Median initial phytoene level , nM 50 29
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restriction, the starting median (25th percentile–75th 
percentile) lycopene level was 670 nM (480–919) for the 
group to take the placebo, and 646 nM (488–890) for the 
group to take the carotenoid-rich TNC. During the sup-
plementation phase, the lycopene level significantly in-
creased in the carotenoid-rich TNC-taking group to a 
median of 1,220 nM (832–1,520) and reached a final me-
dian level of 1,153 nM (847–1,551), whereas no such in-
crease was seen in the placebo group. There, median lev-
els of 690 nM (472–1,017) after 4 weeks and 720 nM (445–
1,040) after 12 weeks were detected.
Similarly, the colorless carotenoid precursor phytoflu-
ene significantly increased in the carotenoid-rich TNC 
arm over time. Median phytofluene was 51 nM (18–94) at 
the end of the washout phase and increased to 178 nM 
(79–329) and to 156 nM (66–390) during the supplemen-
tation phase in the active arm. In contrast, in the placebo 
part of the study, phytofluene was 55 nM (18–108) in the 
depletion phase, which did not significantly change dur-
ing the intake phase to 67 nM (20–117) and 55 nM (20–
108) (Fig. 2b).
Finally, the colorless carotenoid precursor phytoene 
also significantly increased during the intake phase of the 
active arm (Fig. 2c). Median phytoene was 50 nM (18–90) 
at the end of the washout in the group supposed to take 
the active supplement and increased to 90 nM (78–174) 
and to 90 nM (66–154) over the supplementation phase. 
In the placebo group, the initial median phytoene was 29 
nM (16–90). In the supplementation phase, these data did 
not change and were 52 nM (18–90) and 38 nM (18–90).
Whether the determination of the nutritional supple-
ments such as lycopene from blood samples is a good in-
dicator for compliance and/or bioavailability should be 
reconsidered because a significant increase in the corre-
sponding plasma levels not always correlates to a signifi-
cant photoprotection [19]. In this regard, it may be inter-
esting that cutaneous lycopene can also be determined 
noninvasively by Raman spectroscopy [32], where gen-
der-related differences in basal carotene and lycopene 
levels have recently been observed.
The first primary outcome, the MED reading, was 
identical in both intended treatment groups, given as a 
median (min, max) of 0.080 (0.035, 0.125) after the wash-
out phase. After supplementation with carotenoid-rich 
TNC, the MED did not change significantly; we observed 
a median (min, max) of 0.080 (0.035, 0.147; data not 
shown). This negative result is in line with observations 
obtained in a human intervention study over 12 weeks, 
where the MED was compared in a group of 9 females 
with skin type II receiving 55 g tomato corresponding to 
16 mg lycopene in tomato paste to a control group (n = 
8) taking olive oil [33] and in a comparative 10-week 
study, where 10 females consumed either a pill or tomato 
paste corresponding to 16 mg lycopene [34]. In this re-
Screening and
enrollment
(n = 149)
Carotenoid-rich
TNC
(n = 75)
Completed
(n = 71)
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(n = 74)
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(n = 74)
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Withdrew
consent (n = 2)
a b
0 Week
Washout 5 weeks Treatment 12 weeks
X XX
X Informed consent
X Dietary questionary
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X 1.25 × MED irradiation/chromametry
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X Distribution of medication/drug accountability
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X
X
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X
X
XXX
Vis
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Fig. 1. Design of the study. a Overall trial design giving the number of volunteers per protocol and the corre-
sponding dropouts. AEs, adverse events. b Details for both arms of the double-blind, randomized, placebo-con-
trolled, multicenter study as performed in each of the centers. Shown are only those visits at which data were 
collected.
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Fig. 2. Compliance reflected by carotenoid blood levels. Lycopene 
(a) phytofluene (b), and phytoene (c) content in blood samples 
taken at the indicated time points was determined as described in 
Materials and Methods. Given are medians, 75th and 25th percen-
tiles from n = 71 volunteers taking carotenoid-rich TNC and n = 
74 volunteers taking placebo. Significance was determined by 
Kruskal-Wallis one-way ANOVA on ranks (Dunn’s) for each time 
point compared to the starting level at week 5, * p < 0.05 versus 
week 5 (beginning of supplementation).
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Fig. 3. Effect of carotenoid-rich TNC on erythema formation and 
gene expression. a Change of erythema (Δa*) formation was de-
termined by chromametry, as described in Materials and Methods, 
from n = 71 volunteers taking carotenoid-rich TNC and n = 74 
volunteers taking placebo. Δa* is defined as the difference between 
erythema development levels at 24 h following UV irradiation after 
supplementation (visit 8) and erythema development levels at 
24 h following UV irradiation before supplementation (visit 4). 
Given are the differences by box plots with medians (solid line) and 
means (dashed line), dots represent outliers, and error bars repre-
sent the 95th and 5th percentiles. Significance between the treat-
ment groups was determined by the t test; p < 0.05 and as indi-
cated. b Gene expression analysis presented as quotient of gene 
induction after 12 weeks of supplementation with carotenoid-rich 
TNC or placebo (visit 8) divided by gene induction before supple-
mentation (visit 4) from n = 46 volunteers taking carotenoid-rich 
TNC and n = 48 volunteers taking placebo. Given are the quotients 
as box plots with medians; dots represent outliers, and error bars 
represent the 95th and 5th percentiles. Significance between the 
treatment groups was determined by the Mann-Whitney rank sum 
test; p < 0.05 and as indicated. ns, not significant.
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gard, we must keep in mind that the MED was deter-
mined by expert grading in all three studies. Interestingly, 
Rizwan et al. [33] nevertheless observed a significant in-
crease in the erythema index D30 in the tomato paste-con-
suming group employing a reflectance instrument as 
compared to the start conditions.
The second primary outcome was the change of ery-
thema Δa* determined chromametrically (Fig. 3a). Here, 
we observed a significant difference between the two 
treatment groups (n = 71 for carotenoid-rich TNC, and 
n = 74 for placebo). As expected, the change of erythema 
a* after supplementation with carotenoid-rich TNC de-
creased less than after supplementation with placebo. 
This can be seen when we use the difference Δa* of the 
follow-up minus Δa* of the baseline. In case of the carot-
enoid-rich TNC, the response under treatment is lower, 
and we get a difference below zero. In case of the placebo, 
the erythema responses after supplementation are not 
lower, and therefore the difference (follow-up minus 
baseline) is not below zero. These results corroborate a 
previous study where a group of nine volunteers eating 
tomato paste corresponding to 16 mg lycopene, 0.5 mg 
β-carotene, and 0.1 mg lutein over a 10-week period pre-
sented with a significantly decreased Δa* 24 h after 1.25 
MED, while the placebo group of ten people having 10 g 
of olive oil did not [35]. Similarly, comparing the efficacy 
of a 12-week intake of either synthetic lycopene, a tomato 
extract (Lyc-o-Mato), or a drink containing solubilized 
Lyc-o-Mato (Lyc-o-Guard-Drink) in a parallel-group de-
sign (n = 36) indicated a significantly decreased Δa* 24 h 
after a 1.25 MED irradiation in the groups taking approx-
imately 10 mg/day natural lycopene [19].
The difference to MED determination where we failed 
in finding protection by the active supplement may be 
explained by (i) a higher UV dose applied (1.25 MED in-
stead of 1 MED) and by (ii) a higher sensitivity due to an 
objective detection device, as already shown by Rizwan et 
al. [33].
A change of skin color, e.g., skin tanning evaluated as 
ΔL* or ΔITA, was not observed during the study, no mat-
ter whether analyzing the whole population or stratified 
according to seasonal enrollment. The effect of carotene 
intake on skin color is still under debate because contra-
dicting results were observed from having an impact only 
on skin yellowness b* [36, 37] and or redness a* [38].
The lycopene-rich TNC assessed in the current study 
contained 15 mg lycopene, 5.8 mg phytoene and phyto-
fluene, 0.8 mg β-carotene, 5.6 mg tocopherols from to-
mato extract, and 4 mg carnosic acid from rosemary ex-
tract per day because previous in vitro studies/animal 
studies indicated a synergistic inhibition of LPS-induced 
NO production, TNFα-, superoxide and PGE2 release in 
macrophages and in a mouse model of peritonitis by ly-
copene, β-carotene, and the phenolic carnosic acid [39]. 
Similarly, synergistic inhibition of oxidative stress in a 
mouse tumor model [40] or inhibition of androgen sig-
naling and PSA secretion by lycopene and tocopherol 
[41] was determined. In addition, the synergistic effect of 
a TNC and carnosic acid (from rosemary) has recently 
been observed on inhibition of UVB-induced IL6 secre-
tion in keratinocytes as compared to the single interven-
tions (Calniquer et al., unpublished data).
As secondary outcome, we determined UV-induced 
gene upregulation of markers associated with immuno-
suppression or inflammation in biopsies taken at visits 4 
and 8. For ethical reasons, we did not take biopsies from 
all volunteers. Similarly, as for the erythema data Δa* 
(Fig. 2b), we further processed the relative gene expres-
sion data by building a quotient of induction after supple-
mentation divided by induction before supplementation 
(Fig. 2c). For the markers IL-1α and IL10, we did not see 
a significant improvement by supplementation with ca-
rotenoid-rich TNC. In contrast, we saw a significant de-
crease in the UV response after carotenoid-rich TNC in-
take as compared to the placebo treatment. Assessment 
of molecular markers might foster the sensitivity of such 
studies as shown by a significantly decreased expression 
of UV-induced matrix metalloproteinase 1 postsupple-
mentation in the lycopene-taking group as compared to 
the olive oil-taking group [33] or in our previous study 
[6].
Finally, it should be noted that the daily amount of ly-
copene used in the current study corresponds to 52 g 
canned tomato paste and that of β-carotene to 90 g [42]. 
The amount of vitamin E would be obtained by a daily 
intake of 130 g of canned tomato paste [42].
Conclusion
Carotenoid-rich TNC is a safe and well-tolerated nu-
tritional supplement suited for significant protection 
from (i) UVB-induced erythema formation and (ii) UVB-
induced upregulation of IL6 and TNFα.
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